BACKGROUND: The effective management of fatigue in patients with cancer requires a clear delineation of what constitutes nontrivial fatigue. The authors defined numeric cutpoints for fatigue severity based on functional interference and described the prevalence and characteristics of fatigue in patients with cancer and survivors. METHODS: In a multicenter study, outpatients with breast, prostate, colorectal, or lung cancer rated their fatigue severity and symptom interference with functioning on the M. D. Anderson Symptom Inventory numeric scale of 0 to 10. Ratings of symptom interference guided the selection of numeric rating cutpoints between mild, moderate, and severe fatigue levels. Regression analysis identified significant factors related to reporting moderate=severe fatigue . RESULTS: The statistically optimal cutpoints were 4 for moderate fatigue and 7 for severe fatigue. Moderate=severe fatigue was reported by 983 of 2177 patients (45%) undergoing active treatment and was more likely to occur in patients receiving treatment with strong opioids (odds ratio [OR], 3.00), those with a poor Eastern Cooperative Oncology Group performance status (OR, 2.00), those who had >5% weight loss within 6 months (OR, 1.60), those who were receiving >10 medications (OR, 1.58), those with lung cancer (OR, 1.55), and those with a history of depression (OR, 1.42). Among survivors (patients with complete remission or no evidence of disease, and not currently receiving cancer treatment), 29% of patients (150 of 515 patients) had moderate=severe fatigue that was associated with poor performance status (OR, 3.48) and a history of depression (OR, 2.21). CONCLUSIONS: The current study statistically defined fatigue severity categories related to significantly increased symptom interference. The high prevalence of moderate=severe fatigue in both actively treated patients with cancer and survivors warrants the promoting of the routine assessment and management of patient-reported fatigue.
BACKGROUND: The effective management of fatigue in patients with cancer requires a clear delineation of what constitutes nontrivial fatigue. The authors defined numeric cutpoints for fatigue severity based on functional interference and described the prevalence and characteristics of fatigue in patients with cancer and survivors. METHODS: In a multicenter study, outpatients with breast, prostate, colorectal, or lung cancer rated their fatigue severity and symptom interference with functioning on the M. D. Anderson Symptom Inventory numeric scale of 0 to 10. Ratings of symptom interference guided the selection of numeric rating cutpoints between mild, moderate, and severe fatigue levels. Regression analysis identified significant factors related to reporting moderate=severe fatigue . RESULTS: The statistically optimal cutpoints were 4 for moderate fatigue and 7 for severe fatigue. Moderate=severe fatigue was reported by 983 of 2177 patients (45%) undergoing active treatment and was more likely to occur in patients receiving treatment with strong opioids (odds ratio [OR], 3.00), those with a poor Eastern Cooperative Oncology Group performance status (OR, 2.00), those who had >5% weight loss within 6 months (OR, 1.60), those who were receiving >10 medications (OR, 1.58), those with lung cancer (OR, 1.55), and those with a history of depression (OR, 1.42). Among survivors (patients with complete remission or no evidence of disease, and not currently receiving cancer treatment), 29% of patients (150 of 515 patients) had moderate=severe fatigue that was associated with poor performance status (OR, 3.48) and a history of depression (OR, 2.21). CONCLUSIONS: The current study statistically defined fatigue severity categories related to significantly increased symptom interference. The high prevalence of moderate=severe fatigue in both actively treated patients with cancer and survivors warrants the promoting of the routine assessment and management of patient-reported fatigue.
Authors: Wendy H Oldenmenger; Pleun J de Raaf; Cora de Klerk; Carin C D van der Rijt Journal: J Pain Symptom Manage Date: 2012-09-25 Impact factor: 3.612
Authors: Daniel L Patrick; Sandra L Ferketich; Paul S Frame; Jesse J Harris; Carolyn B Hendricks; Bernard Levin; Michael P Link; Craig Lustig; Joseph McLaughlin; L Douglas Reid; Andrew T Turrisi; Jürgen Unützer; Sally W Vernon Journal: J Natl Cancer Inst Monogr Date: 2004
Authors: Maarten Hofman; Gary R Morrow; Joseph A Roscoe; Jane T Hickok; Karen M Mustian; Dennis F Moore; James L Wade; Tom R Fitch Journal: Cancer Date: 2004-08-15 Impact factor: 6.860
Authors: Jennifer M Jones; Karin Olson; Pamela Catton; Charles N Catton; Neil E Fleshner; Monika K Krzyzanowska; David R McCready; Rebecca K S Wong; Haiyan Jiang; Doris Howell Journal: J Cancer Surviv Date: 2015-04-16 Impact factor: 4.442
Authors: Peter J Esau; Elizabeth M Gittemeier; Alexander B Opoku-Acheampong; Korynne S Rollins; Dryden R Baumfalk; David C Poole; Timothy I Musch; Bradley J Behnke; Steven W Copp Journal: Am J Cancer Res Date: 2017-12-01 Impact factor: 6.166
Authors: Maria Pisu; Wendy Demark-Wahnefried; Kelly M Kenzik; Robert A Oster; Chee Paul Lin; Sharon Manne; Ronald Alvarez; Michelle Y Martin Journal: J Cancer Surviv Date: 2017-01-09 Impact factor: 4.442
Authors: Qiuling Shi; Ju-Whei Lee; Xin Shelley Wang; Michael J Fisch; Victor T Chang; Lynne Wagner; Charles S Cleeland Journal: JCO Oncol Pract Date: 2020-05-05
Authors: Roxanne E Jensen; Arnold L Potosky; Carol M Moinpour; Tania Lobo; David Cella; Elizabeth A Hahn; David Thissen; Ashley Wilder Smith; Jaeil Ahn; George Luta; Bryce B Reeve Journal: J Clin Oncol Date: 2017-04-20 Impact factor: 44.544
Authors: Jinbo Yue; Qiuling Shi; Ting Xu; Melenda Jeter; Ting-Yu Chen; Ritsuko Komaki; Daniel R Gomez; Tinsu Pan; Charles S Cleeland; Zhongxing Liao; Xin Shelley Wang Journal: Qual Life Res Date: 2018-03-16 Impact factor: 4.147
Authors: David Cella; Seung Choi; Sofia Garcia; Karon F Cook; Sarah Rosenbloom; Jin-Shei Lai; Donna Surges Tatum; Richard Gershon Journal: Qual Life Res Date: 2014-06-18 Impact factor: 4.147
Authors: Ann M Berger; Kathi Mooney; Amy Alvarez-Perez; William S Breitbart; Kristen M Carpenter; David Cella; Charles Cleeland; Efrat Dotan; Mario A Eisenberger; Carmen P Escalante; Paul B Jacobsen; Catherine Jankowski; Thomas LeBlanc; Jennifer A Ligibel; Elizabeth Trice Loggers; Belinda Mandrell; Barbara A Murphy; Oxana Palesh; William F Pirl; Steven C Plaxe; Michelle B Riba; Hope S Rugo; Carolina Salvador; Lynne I Wagner; Nina D Wagner-Johnston; Finly J Zachariah; Mary Anne Bergman; Courtney Smith Journal: J Natl Compr Canc Netw Date: 2015-08 Impact factor: 11.908